Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series

Mhd Louai Manini, Michael Camilleri, Rayna Grothe, Carlo Di Lorenzo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Gastrointestinal (GI) motility disorders are common in children. Treatment is challenging with limited medical and surgical options. Pyridostigmine, an acetyl cholinesterase inhibitor, increases acetylcholine at the neuromuscular junction promoting intestinal contractions. Little is known about the role and dosing of pyridostigmine in pediatric GI motility disorders. Methods: We present a case series of children with GI dysmotility managed with oral pyridostigmine. Patients’ diagnoses include chronic intestinal pseudo-obstruction, gastroparesis with delayed small bowel transit, chronic constipation with failure to thrive, and prolonged ileus after pelvic surgery with chronic opioid use. Results: Pyridostigmine was effective and safe in all cases. Pyridostigmine decreased abdominal distention, increased bowel movement frequency, and improved enteral feeding tolerance. Effective dosing ranged between 0.25–2.0 mg/kg/day. One patient experienced cramping abdominal pain while on pyridostigmine, but pain resolved after medication was discontinued. Conclusion: We found oral pyridostigmine to be helpful in children with different GI motility problems. Pyridostigmine should be considered in such patients when other treatment interventions have not been beneficial.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalPediatric Drugs
DOIs
StateAccepted/In press - Dec 14 2017

Fingerprint

Pyridostigmine Bromide
Gastrointestinal Motility
Pediatrics
Gastroparesis
Intestinal Pseudo-Obstruction
Failure to Thrive
Ileus
Neuromuscular Junction
Cholinesterase Inhibitors
Enteral Nutrition
Constipation
Abdominal Pain
Opioid Analgesics
Acetylcholine
Pain

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Pharmacology (medical)

Cite this

Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders : A Case Series. / Manini, Mhd Louai; Camilleri, Michael; Grothe, Rayna; Di Lorenzo, Carlo.

In: Pediatric Drugs, 14.12.2017, p. 1-8.

Research output: Contribution to journalArticle

@article{c633e8b2ef654590938215ab6b393ec4,
title = "Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders: A Case Series",
abstract = "Background: Gastrointestinal (GI) motility disorders are common in children. Treatment is challenging with limited medical and surgical options. Pyridostigmine, an acetyl cholinesterase inhibitor, increases acetylcholine at the neuromuscular junction promoting intestinal contractions. Little is known about the role and dosing of pyridostigmine in pediatric GI motility disorders. Methods: We present a case series of children with GI dysmotility managed with oral pyridostigmine. Patients’ diagnoses include chronic intestinal pseudo-obstruction, gastroparesis with delayed small bowel transit, chronic constipation with failure to thrive, and prolonged ileus after pelvic surgery with chronic opioid use. Results: Pyridostigmine was effective and safe in all cases. Pyridostigmine decreased abdominal distention, increased bowel movement frequency, and improved enteral feeding tolerance. Effective dosing ranged between 0.25–2.0 mg/kg/day. One patient experienced cramping abdominal pain while on pyridostigmine, but pain resolved after medication was discontinued. Conclusion: We found oral pyridostigmine to be helpful in children with different GI motility problems. Pyridostigmine should be considered in such patients when other treatment interventions have not been beneficial.",
author = "Manini, {Mhd Louai} and Michael Camilleri and Rayna Grothe and {Di Lorenzo}, Carlo",
year = "2017",
month = "12",
day = "14",
doi = "10.1007/s40272-017-0277-6",
language = "English (US)",
pages = "1--8",
journal = "Paediatric Drugs",
issn = "1174-5878",
publisher = "Adis International Ltd",

}

TY - JOUR

T1 - Application of Pyridostigmine in Pediatric Gastrointestinal Motility Disorders

T2 - A Case Series

AU - Manini, Mhd Louai

AU - Camilleri, Michael

AU - Grothe, Rayna

AU - Di Lorenzo, Carlo

PY - 2017/12/14

Y1 - 2017/12/14

N2 - Background: Gastrointestinal (GI) motility disorders are common in children. Treatment is challenging with limited medical and surgical options. Pyridostigmine, an acetyl cholinesterase inhibitor, increases acetylcholine at the neuromuscular junction promoting intestinal contractions. Little is known about the role and dosing of pyridostigmine in pediatric GI motility disorders. Methods: We present a case series of children with GI dysmotility managed with oral pyridostigmine. Patients’ diagnoses include chronic intestinal pseudo-obstruction, gastroparesis with delayed small bowel transit, chronic constipation with failure to thrive, and prolonged ileus after pelvic surgery with chronic opioid use. Results: Pyridostigmine was effective and safe in all cases. Pyridostigmine decreased abdominal distention, increased bowel movement frequency, and improved enteral feeding tolerance. Effective dosing ranged between 0.25–2.0 mg/kg/day. One patient experienced cramping abdominal pain while on pyridostigmine, but pain resolved after medication was discontinued. Conclusion: We found oral pyridostigmine to be helpful in children with different GI motility problems. Pyridostigmine should be considered in such patients when other treatment interventions have not been beneficial.

AB - Background: Gastrointestinal (GI) motility disorders are common in children. Treatment is challenging with limited medical and surgical options. Pyridostigmine, an acetyl cholinesterase inhibitor, increases acetylcholine at the neuromuscular junction promoting intestinal contractions. Little is known about the role and dosing of pyridostigmine in pediatric GI motility disorders. Methods: We present a case series of children with GI dysmotility managed with oral pyridostigmine. Patients’ diagnoses include chronic intestinal pseudo-obstruction, gastroparesis with delayed small bowel transit, chronic constipation with failure to thrive, and prolonged ileus after pelvic surgery with chronic opioid use. Results: Pyridostigmine was effective and safe in all cases. Pyridostigmine decreased abdominal distention, increased bowel movement frequency, and improved enteral feeding tolerance. Effective dosing ranged between 0.25–2.0 mg/kg/day. One patient experienced cramping abdominal pain while on pyridostigmine, but pain resolved after medication was discontinued. Conclusion: We found oral pyridostigmine to be helpful in children with different GI motility problems. Pyridostigmine should be considered in such patients when other treatment interventions have not been beneficial.

UR - http://www.scopus.com/inward/record.url?scp=85038114993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038114993&partnerID=8YFLogxK

U2 - 10.1007/s40272-017-0277-6

DO - 10.1007/s40272-017-0277-6

M3 - Article

C2 - 29243034

AN - SCOPUS:85038114993

SP - 1

EP - 8

JO - Paediatric Drugs

JF - Paediatric Drugs

SN - 1174-5878

ER -